Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
Komal L. Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X. Ma, Erika P. Hamilton, Cynthia Osborne, Manali Bhave, Peter A. Kaufman, J. Thaddeus Beck, Luis Manso Sanchez, Ritesh Parajuli, Hwei Chung Wang, Jessica J. Tao, Seock Ah Im, Kathleen Harnden, Kan Yonemori, Ajay Dhakal, Patrick Neven, Philippe Aftimos, Jean Yves-PiergaYen Shen Lu, Timothy Larson, Yolanda Jerez, Kostandinos Sideras, Joohyuk Sohn, Sung Bae Kim, Cristina Saura, Aditya Bardia, Sarah L. Sammons, Francesca Bacchion, Yujia Li, Eunice Yuen, Shawn T. Estrem, Vanessa Rodrik-Outmezguine, Bastien Nguyen, Roohi Ismail-Khan, Lillian Smyth, Muralidhar Beeram
Dive into the research topics of 'Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study'. Together they form a unique fingerprint.